Nothing Special   »   [go: up one dir, main page]
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Context-dependent adaption of EpCAM expression in early systemic esophageal cancer

Oncogene volume 33, pages 4904–4915 (2014)Cite this article

Subjects

Abstract

The role of the epithelial cell adhesion molecule EpCAM in cancer progression remains largely unclear. High expression of EpCAM in primary tumors is often associated with more aggressive phenotypes and EpCAM is the prime epithelial antigen in use to isolate circulating tumor cells (CTCs) and characterize disseminated tumor cells (DTCs). However, reduced expression of EpCAM was associated with epithelial-to-mesenchymal transition (EMT) and reports on a lack of EpCAM on CTCs emerged. These contradictory observations might reflect a context-dependent adaption of EpCAM expression during metastatic progression. To test this, EpCAM expression was monitored in esophageal cancer at different sites of early systemic disease. Although most of the primary esophageal tumors expressed high levels of EpCAM, the majority of DTCs in bone marrow lacked EpCAM. In vitro, downregulation of EpCAM expression at the plasma membrane was observed in migrating and invading cells, and was associated with a partial loss of the epithelial phenotype and with significantly decreased proliferation. Accordingly, induction of EMT through the action of TGFβ resulted in substantial loss of EpCAM cell surface expression on esophageal cancer cells. Knock-down or natural loss of EpCAM recapitulated these effects as it reduced proliferation while enhancing migration and invasion of cancer cells. Importantly, expression of EpCAM on DTCs was significantly associated with the occurrence of lymph node metastases and with significantly decreased overall survival of esophageal cancer patients. We validated this observation by showing that high expression of EpCAM promoted tumor outgrowth after xenotransplantation of esophageal carcinoma cells. The present data disclose a dynamic expression of EpCAM throughout tumor progression, where EpCAMhigh phenotypes correlate with proliferative stages, whereas EpCAMlow/negative phenotypes associated with migration, invasion and dissemination. Thus, differing expression levels of EpCAM must be taken into consideration for therapeutic approaches and during clinical retrieval of disseminated tumor cells.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Stoecklein NH, Klein CA. . Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer 2010; 126: 589–598.

    Article  CAS  Google Scholar 

  2. Sleeman J, Steeg PS . Cancer metastasis as a therapeutic target. Eur J Cancer 2010; 46: 1177–1180.

    Article  CAS  Google Scholar 

  3. Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.

    Article  CAS  Google Scholar 

  4. Pantel K, Brakenhoff RH, Brandt B . Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008; 8: 329–340.

    Article  CAS  Google Scholar 

  5. Floor SL, Dumont JE, Maenhaut C, Raspe E . Hallmarks of cancer: of all cancer cells, all the time? Trends Mol Med 2012; 18: 509–515.

    Article  CAS  Google Scholar 

  6. Hanahan D, Weinberg RA . The hallmarks of cancer. Cell 2000; 100: 57–70.

    Article  CAS  Google Scholar 

  7. Imrich S, Hachmeister M, Gires O . EpCAM and its potential role in tumor-initiating cells. Cell Adh Migr 2012; 6: 30–38.

    Article  Google Scholar 

  8. Patriarca C, Macchi RM, Marschner AK, Mellstedt H . Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 2012; 38: 68–75.

    Article  CAS  Google Scholar 

  9. Munz M, Baeuerle PA, Gires O . The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009; 69: 5627–5629.

    Article  CAS  Google Scholar 

  10. Winter MJ, Cirulli V, Briaire-de Bruijn IH, Litvinov SV . Cadherins are regulated by Ep-CAM via phosphaditylinositol-3 kinase. Mol Cell Biochem 2007; 302: 19–26.

    Article  CAS  Google Scholar 

  11. Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de Bruijn IH, Prins F et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 1997; 139: 1337–1348.

    Article  CAS  Google Scholar 

  12. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O . The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004; 23: 5748–5758.

    Article  Google Scholar 

  13. Chaves-Perez A, Mack B, Maetzel D, Kremling H, Eggert C, Harreus U et al. EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene 2012; 32: 641–650.

    Article  Google Scholar 

  14. Gonzalez B, Denzel S, Mack B, Conrad M, Gires O . EpCAM is involved in maintenance of the murine embryonic stem cell phenotype. Stem Cells 2009; 27: 1782–1791.

    Article  CAS  Google Scholar 

  15. Ng VY, Ang SN, Chan JX, Choo AB . Characterization of epithelial cell adhesion molecule as a surface marker on undifferentiated human embryonic stem cells. Stem Cells 2009; 28: 29–35.

    Article  Google Scholar 

  16. Lu TY, Lu RM, Liao MY, Yu J, Chung CH, Kao CF et al. Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. J Biol Chem 2010; 285: 8719–8732.

    Article  CAS  Google Scholar 

  17. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11: 162–171.

    Article  CAS  Google Scholar 

  18. Klein CA, Stoecklein NH . Lessons from an aggressive cancer: evolutionary dynamics in esophageal carcinoma. Cancer Res 2009; 69: 5285–5288.

    Article  CAS  Google Scholar 

  19. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z . TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005; 6: 56.

    Article  Google Scholar 

  20. van der Gun BT, Melchers LJ, Ruiters MH, De Leij LF, McLaughlin PM, Rots MG . EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 2010; 31: 1913–1921.

    Article  CAS  Google Scholar 

  21. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006; 94: 128–135.

    Article  CAS  Google Scholar 

  22. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004; 35: 122–128.

    Article  CAS  Google Scholar 

  23. Stoecklein NH, Siegmund A, Scheunemann P, Luebke AM, Erbersdobler A, Verde PE et al. EpCAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. BMC Cancer 2006; 6: 165.

    Article  Google Scholar 

  24. Baeuerle PA, Gires O . EpCAM (CD326) finding its role in cancer. Br J Cancer 2007; 96: 417–423.

    Article  CAS  Google Scholar 

  25. Kimura H, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y et al. Prognostic significance of EpCAM expression in human esophageal cancer. Int J Oncol 2007; 30: 171–179.

    CAS  PubMed  Google Scholar 

  26. Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH . Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 2005; 92: 1767–1772.

    Article  CAS  Google Scholar 

  27. Vannier C, Mock K, Brabletz T, Driever W . Zeb1 regulates E-cadherin and Epcam expression to control cell behavior in early zebrafish development. J Biol Chem 2013; 288: 18643–18659.

    Article  CAS  Google Scholar 

  28. Rao CG, Chianese D, Doyle GV, Miller MC, Russell T, Sanders RA Jr. et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 2005; 27: 49–57.

    CAS  PubMed  Google Scholar 

  29. Gorges TM, Tinhofer I, Drosch M, Rose L, Zollner TM, Krahn T et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 2012; 12: 178.

    Article  CAS  Google Scholar 

  30. Alix-Panabieres C, Riethdorf S, Pantel K . Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 2008; 14: 5013–5021.

    Article  CAS  Google Scholar 

  31. Enzinger PC, Mayer RJ . Esophageal cancer. N Engl J Med. 2003; 349: 2241–2252.

    Article  CAS  Google Scholar 

  32. Bao B, Wang Z, Ali S, Kong D, Banerjee S, Ahmad A et al. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem 2011; 112: 2296–2306.

    Article  CAS  Google Scholar 

  33. Biddle A, Liang X, Gammon L, Fazil B, Harper LJ, Emich H et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 2011; 71: 5317–5326.

    Article  CAS  Google Scholar 

  34. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002; 360: 683–689.

    Article  CAS  Google Scholar 

  35. Raffel A, Eisenberger CF, Cupisti K, Schott M, Baldus SE, Hoffmann I et al. Increased EpCAM expression in malignant insulinoma: potential clinical implications. Eur J Endocrinol 2010; 162: 391–398.

    Article  CAS  Google Scholar 

  36. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 2006; 66: 2116–2128.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This project was funded by The Wilhelm-Sander-Stiftung (2009.083.1), in part by the Deutsche Forschungsgemeinschaft (DFG STO464/2-2), the Rudolf-Bartling Stiftung (II/89). We thank Christof Seifarth for excellent technical support.

Author contributions

CD and HK performed and analyzed experiments related to EpCAM in vitro and in xenotransplantations. JW, NL and SAB performed and analyzed experiments in primary tumors. SS and DW performed and analyzed experiments on DTCs. KR, CV and SB contributed to experiments, DV, UH, SAB and WTK provided clinical material and clinical data analysis related to EpCAM in primary tumors and in DTCs in patients. PP contributed to EpCAM in vitro experiments. VH and JP contributed to xenotransplantation experiments. NHS and OG designed the experiments, analyzed the data and wrote the manuscript.

Author information

Author notes

  1. C Driemel and H Kremling: The authors contributed equally to this work and are listed in alphabetical order.

  2. N H Stoecklein and O Gires: Both authors equally contributed.

Authors and Affiliations

  1. Department for General, Visceral und Pediatric Surgery, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany

    C Driemel, S Schumacher, J Wolters, N Lindenlauf, V Hoya, J M Pietsch, P Panagiotidou, C Vay, D Vallböhmer, W T Knoefel & N H Stoecklein

  2. Department of Otorhinolaryngology, Head and Neck Surgery, Grosshadern Medical Center, Ludwig-Maximilians University of Munich, Munich, Germany

    H Kremling, D Will, B Mack, U Harréus & O Gires

  3. Institute for Pathology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany

    S A Baldus

  4. Institute for Transplantation Diagnostics and Cellular Therapy, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany

    K Raba

Authors
  1. C Driemel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Kremling
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Schumacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Will
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Wolters
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Lindenlauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Mack
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S A Baldus
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. V Hoya
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J M Pietsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P Panagiotidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. K Raba
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. C Vay
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. D Vallböhmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. U Harréus
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. W T Knoefel
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. N H Stoecklein
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. O Gires
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O Gires.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Driemel, C., Kremling, H., Schumacher, S. et al. Context-dependent adaption of EpCAM expression in early systemic esophageal cancer. Oncogene 33, 4904–4915 (2014). https://doi.org/10.1038/onc.2013.441

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2013.441

Keywords

This article is cited by

Search

Advanced search

Quick links